OncoNano Medicine, Inc. — SEC Form D Filing

OncoNano Medicine, Inc. filed an SEC Form D on October 8, 2026, reporting $10.05M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 8, 2026
Amount reported
$10.05M
Round stage
Series B due to securing a $10M equity round to advance clinical trial pipelines for its lead surgical imaging agent.
Industry
Biotechnology
Website
https://onconanomed.com

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Surgeons struggle to precisely differentiate malignant tumor margins from healthy surrounding tissue in real time during surgical resections.

Solution

OncoNano Medicine develops pH-responsive fluorescent nanoprobes that light up acidic tumor environments under near-infrared light for accurate intraoperative visualization and targeted drug delivery.

Why now

Recent breakthroughs in nanoscale pH-sensing materials enable real-time targeted intraoperative imaging that was previously impossible with conventional fluorescent dyes.

Source: SEC EDGAR Form D filing